Ocular Therapeutix^™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI^™ in Wet AMD

Ocular Therapeutix, Inc. announced that the US FDA has agreed to a SPA Agreement Modification for the Company’s pivotal Phase III SOL clinical trial of AXPAXLI^™ for the treatment of wet age-related macular degeneration.